The objective of this guideline from the Canadian Fertility and Andrology Society is to synthesize the evidence on preimplantation genetic testing for aneuploidies (PGT-A) using trophectoderm biopsy and 24-chromosome analysis and to provide clinical recommendations using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) framework. To date, randomized controlled trials have been limited to good-prognosis patients who were able to generate two or more blastocysts for biopsy. In this specific population the GRADE analysis of PGT-A shows an increase in the implantation rate and ongoing pregnancy or delivery rate per transfer. Clearly, it is difficult to generalize from this subgroup of patients to the infertility population at large. As a result, the application of PGT-A should be individualized, and patient factors such as age and ability to generate embryos will influence decision-making. Comprehensive patient counselling and informed consent are imperative before undertaking PGT-A. Potential benefits must be weighed against the costs and limitations of the technology, including the risk of embryo damage, false positives, false negatives and the detection of embryonic mosaicism. Future research is required, especially with regard to the use of PGT-A in poorer prognosis patients, and with respect to reporting outcomes per cycle start and cumulatively per retrieval.

加拿大生育与男科学会的本指南旨在综合使用滋养外胚层活检和 24 染色体分析的非整倍体植入前基因检测 (PGT-A) 的证据，并使用推荐分级评估、发展和分析提供临床建议。评估 (GRADE) 框架。迄今为止，随机对照试验仅限于能够产生两个或更多用于活检的囊胚的预后良好的患者。在这个特定人群中，PGT-A 的 GRADE 分析显示植入率和每次转移的持续妊娠或分娩率增加。显然，很难将这一亚组患者推广到整个不育人群。因此，PGT-A的应用应个体化，年龄和产生胚胎的能力等患者因素将影响决策。在进行 PGT-A 之前，必须进行全面的患者咨询和知情同意。必须权衡潜在收益与该技术的成本和局限性，包括胚胎损伤、假阳性、假阴性和胚胎嵌合检测的风险。需要进一步研究，尤其是在预后较差的患者中使用 PGT-A，以及报告每个周期开始和每次检索累积的结果。包括胚胎损伤的风险、假阳性、假阴性和胚胎嵌合体的检测。需要进一步研究，尤其是在预后较差的患者中使用 PGT-A，以及报告每个周期开始和每次检索累积的结果。包括胚胎损伤的风险、假阳性、假阴性和胚胎嵌合体的检测。需要进一步研究，尤其是在预后较差的患者中使用 PGT-A，以及报告每个周期开始和每次检索累积的结果。